Equillium_Square_Logo.png
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
10 nov. 2020 16h05 HE | Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Present at Investor Conferences in November 2020
10 nov. 2020 08h35 HE | Equillium
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus
04 nov. 2020 08h35 HE | Equillium
Studies further validate ongoing clinical development of itolizumab for the treatment of systemic lupus erythematosus and lupus nephritis LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) --...
Equillium_Square_Logo.png
Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020
17 sept. 2020 16h07 HE | Equillium
LA JOLLA, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference
03 sept. 2020 16h07 HE | Equillium
LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium Announces Pricing of Public Offering of Common Stock
13 août 2020 21h42 HE | Equillium
LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Present at BTIG Virtual Biotechnology Conference 2020
30 juil. 2020 16h07 HE | Equillium
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference
07 mai 2020 16h07 HE | Equillium
LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
30 mars 2020 16h07 HE | Equillium
LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_Square_Logo.png
Equillium Strengthens Leadership Team with Key Appointments
27 févr. 2020 16h13 HE | Equillium
Maple Fung, M.D., joins as vice president clinical developmentMatthew Ritter, Ph.D., joins as vice president corporate development LA JOLLA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Equillium,...